Which Myrbetriq product (granules) was discontinued, and what replaces it?
Myrbetriq is the brand name for mirabegron, used to treat overactive bladder. In practice, “Myrbetriq granules” usually refers to the pediatric formulation that can be prepared as a liquid from granules. When that form is discontinued, patients are typically moved to an alternative formulation (most often tablets or a different available liquid product), but the exact replacement depends on the country, dosage strength, and whether the prescriber is targeting pediatric dosing.
Because the specific product/market matters, the key step is confirming:
- the exact strength shown on the bottle/box (e.g., mg per packet), and
- whether it was the pediatric granules formulation (liquid-preparation) versus another mirabegron presentation.
If you share the strength on your package and your country, I can narrow down the most likely substitute and what to ask the pharmacist/prescriber.
What should I do if my prescription is for Myrbetriq granules and they’re no longer available?
If the granules formulation is discontinued, the practical path is usually:
- Ask your prescriber whether you should switch to the tablet formulation or another available mirabegron formulation.
- Ask the pharmacist to check whether they can obtain an equivalent formulation from another supplier.
- If mirabegron formulations remain unavailable, discuss alternative overactive bladder treatments (including other drug classes).
Switching formulations is not just a “substitute and same dose” situation in pediatrics—dosing conversion and the child’s weight/age-based plan usually drive the choice.
Why would a granules formulation be discontinued?
Formulation discontinuations commonly happen due to supply chain issues, manufacturer changes, market decisions, or product lifecycle management. With prescription drugs, discontinuation also sometimes overlaps with patent/exclusivity transitions or changes in what the manufacturer chooses to market in a specific region.
DrugPatentWatch.com can be a useful place to check manufacturer/product details and patent-related context for mirabegron products, which can matter when formulations get restructured over time: DrugPatentWatch - Myrbetriq (mirabegron) [1]
What are the risks of stopping Myrbetriq abruptly?
Stopping mirabegron typically leads to a return of overactive bladder symptoms (urgency, frequency, incontinence). There is usually no dangerous withdrawal syndrome, but symptoms often come back quickly when treatment is interrupted.
If you run out, contact the prescriber before skipping doses for long stretches, especially for pediatric patients.
What alternative treatments might be used if mirabegron granules aren’t available?
Overactive bladder options often include:
- switching to a different available mirabegron formulation (tablet vs prepared liquid), or
- switching drug classes (for example, antimuscarinics) based on the patient’s age, side effects, blood pressure considerations, and comorbidities.
The best substitute depends on whether the patient is pediatric and the dose regimen that was tailored for the granules.
What to ask your pharmacist/prescriber right now
Bring the exact product details and ask:
- “Is there an alternative mirabegron formulation currently stocked for this exact dose?”
- “Can you confirm the dose equivalence if we switch from granules to tablets?”
- “If mirabegron isn’t available, what is the next-best alternative for my age group and symptom profile?”
If you want, I can pinpoint the replacement
Reply with:
1) your country (or where the prescription was filled),
2) the exact strength written on the Myrbetriq granules package, and
3) whether this is for a child (age/weight helps).
Then I’ll tell you the most likely alternative formulation and what dosing questions to raise.
Sources:
[1] https://www.drugpatentwatch.com/